Concurrent use of hydroxyurea and deferasirox in Californians with sickle cell disease-Reference-Cited by-同舟云学术

Concurrent use of hydroxyurea and deferasirox in Californians with sickle cell disease

Published:2021-07-14 Issue:3 Volume:4 Page:
ISSN:2398-8835
Container-title:Health Science Reports
language:en
Short-container-title:Health Sci Rep

Author:

Wong Trisha E.¹^ORCID,Valle Jhaqueline²,Paulukonis Susan²

Affiliation:

1. Division of Pediatric Hematology/Oncology and Department of Pathology Oregon Health and Sciences University Portland Oregon USA

2. Tracking California Public Health Institute Richmond California USA

Funder

BCCDC Foundation for Public Health

Centers for Disease Control and Prevention

Pfizer

Sanofi

Publisher

Wiley

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hsr2.323

Reference15 articles.

1. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease

2. Patient-Reported Outcomes of Deferasirox (Exjade®, ICL670) versus Deferoxamine in Sickle Cell Disease Patients with Transfusional Hemosiderosis

3. Update on the use of hydroxyurea therapy in sickle cell disease

4. BuchananGRY BarbaraP.Evidence‐Based Management of Sickle Cell Disease: Expert Panel Report: National Institute of Health;2014.https://www.nhlbi.nih.gov/sites/default/files/media/docs/sickle-cell-disease-report%20020816_0.pdf

5. DebaunMW.The TWiTCH Trial [Podcast]. American Society of Hematology;2016.https://www.hematology.org/Thehematologist/Diffusion/4943.aspx

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ferroptosis as an emerging target in sickle cell disease;Current Research in Toxicology;2024

2. Improving Outcomes for Patients With Sickle Cell Disease in the United States;JAMA Health Forum;2021-10-29